- TLDR Biotech
- Archive
- Page 1
The Latest Biotech & Pharma Updates
Biotech & Pharma Updates | January 25 - 26, 2026
🧬 Sarepta Therapeutics' Elevidys gene therapy shows sustained benefits three years post-treatment in Ph3 Duchenne muscular dystrophy trial, Recipharm debuts new Bengaluru facility for beta-lactam drugs to meet tougher FDA contamination standards, 1stBio Therapeutics raises $22M Series D for HPK1 inhibitor clinical development, Fortitude Biomedicines launches with $13M seed to combine molecular glues with ADCs for next-generation cancer and autoimmune therapies, HanchorBio + WuXi Biologics partner on strategic collaboration for bi- and multi-functional fusion protein development, GSK's Arexvy receives European approval expansion for respiratory syncytial virus prevention in all adults 18 and older
Biotech & Pharma Updates | January 22 - 25, 2026
🧬 Novo Nordisk's oral Wegovy shows very strong launch with 18,410 weekly prescriptions - surpassing other GLP-1s, ST Pharm secures $56M API manufacturing contract with undisclosed US biotech for oligonucleotide treatment, NICE reverses decision to recommend NHS funding for Pfizer's Talzenna with Xtandi for advanced prostate cancer, US House of Representatives passes $1.2T spending bill that could restart FDA's rare pediatric disease priority voucher program, GSK's Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) wins China approval for uncontrolled asthma treatment
Biotech & Pharma Updates | January 21 - 22, 2026
🧬 Samsung Biologics becomes first Korean biopharma to surpass 2 trillion won ($1.36B) profit threshold in 2025, Sandoz eyes $322B biosimilar opportunity as 50+ biologics lose patent protection in golden decade ahead, global pharma manufacturing output surged 9.1% in 2025 due to US tariff threat front-loading activities, Corxel Pharmaceuticals raises $287M Series D1 for obesity pill development and testing, BioMarin veterans launch Mendra with $82M Series A to use AI for rare disease drug development, Corcept Therapeutics' relacorilant shows Ph3 overall survival benefit in platinum-resistant ovarian cancer, Bristol Myers Squibb + Janux Therapeutics partner on tumor-activated cancer drugs, $50M upfront, $850M total deal value
Biotech & Pharma Updates | January 20 - 21, 2026
🧬 J&J targets $100B revenue for 2026, overcoming Stelara patent cliff with oncology growth, Insilico Medicine + Hygtia Therapeutics split rights for preclinical NLRP3 inhibitor - $10M upfront + $56M milestones, Otsuka gains EU approval for Dawnzera (donidalorsen) targeting prekallikrein for hereditary angioedema prevention following Ph3 results, Infinitopes raises $35.1M seed total for oesophageal cancer vaccine trial preparation, Bristol Myers Squibb + Microsoft partner on AI-powered lung cancer detection network, FDA launches PreCheck pilot program to streamline US drug manufacturing facility approval process starting February 1
Biotech & Pharma Updates | January 19 - 20, 2026
🧬 GSK acquires RAPT Therapeutics for $2.2B - targeting food allergy market with ozureprubart antibody, Roche doubles Genentech's North Carolina facility investment to $2B targeting obesity treatments by 2029, Exciva raises $59M Series B for neuropsychiatric treatments + Alzheimer's agitation therapy, Moderna and Merck & Co.'s intismeran autogene plus Keytruda maintains 49% risk reduction in advanced melanoma Ph2 study, Pfizer sell ViiV Healthcare stake to Shionogi in deal worth $2.1 billion
Biotech & Pharma Updates | January 18 - 19, 2026
🧬 Sharp Services invests over €20 million ($23.2M) to expand European injectables packaging capacity amid strong market demand, Cytotheryx raises $60M Series A to develop cell therapy treatments for liver disease, Nxera Pharma reports positive Ph3 results for Quviviq (daridorexant) targeting orexin receptors in insomnia patients, Syngene International + Bristol Myers Squibb extend research collaboration through 2035 covering discovery to commercialization, Astellas Pharma's zolbetuximab receives Scottish Medicines Consortium approval for CLDN18.2-positive gastric cancer treatment
Biotech & Pharma Updates | January 15 - 18, 2026
🧬 Novo Nordisk's oral Wegovy shows strong early prescription uptake - outpacing rival Eli Lilly's Zepbound launch, AgomAb Therapeutics files $100M US IPO - ALK5 inhibitors for inflammatory diseases, ImmunityBio reports promising Ph1 results for CD19 CAR-NK cell therapy in Waldenström macroglobulinemia, AbelZeta + AstraZeneca expand GPC3 CAR-T therapy partnership with $630M China rights acquisition, Sobi's Aspaveli (pegcetacoplan) receives EU approval for C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis
Biotech & Pharma Updates | January 14 - 15, 2026
🧬 Novo Nordisk Foundation commits $856M funding for Danish life science incubator BioInnovation Institute, Sanofi reportedly prepares renewed takeover bid for Ocular Therapeutix after rejecting $16-per-share offer, Oxford Biomedica confirms takeover talks with private equity group EQT after rejecting previous low offers, BD invests $110M to expand Nebraska syringe production amid rising GLP-1 and biologics demand, Ocugen's OCU410 gene therapy shows 46% lesion growth reduction in Ph2 trial for geographic atrophy, BMS Immunai collaborate on AI-powered immune system analysis using AMICA-OS platform (terms undisclosed), Sanofi's Myqorzo (aficamten) and Redemplo (plozasiran) win China approval for obstructive hypertrophic cardiomyopathy and familial chylomicronaemia syndrome
Biotech & Pharma Updates | January 13 - 14, 2026
🧬 Novo Nordisk refocuses core business on diabetes and obesity - pulling back from unrelated indications, Eli Lilly expects second-quarter 2026 FDA decision on orforglipron obesity pill with priority voucher review, Sino Biopharmaceutical to acquire Hygieia Biomedical for $172M to expand siRNA chronic disease pipeline, Servier launches Servier Ventures with €200M ($232.8M) fund for oncology/neurology biotechs, Caldera Therapeutics launches with $112.5M funding and dual-targeting inflammatory bowel disease drug from China's Qyuns, Johnson & Johnson's Tecvayli (teclistamab) shows Ph3 success targeting BCMA in relapsed multiple myeloma patients, Jazz Pharmaceuticals sells priority review voucher from Modeyso approval for $200 million
Biotech & Pharma Updates | January 12 - 13, 2026
🧬 AbbVie commits $100B US R&D investment over 10 years - wins tariff and pricing exemptions, AstraZeneca acquires Modella AI to integrate multimodal foundation models into its oncology R&D operations, Proxima raises $80M seed for AI-powered proximity-based therapeutics for undruggable targets, Illumina + AstraZeneca + Merck & Co. + Eli Lilly partner on Billion Cell Atlas for AI drug discovery, Nuclera extends Series C to $87M for antibody engineering platform development, ImmunityBio's ANKTIVA (nogapendekin alfa inbakicept) shows positive Ph2/Ph3 results in non-small cell lung cancer, Novartis + Zonsen PepLib Biotech partner on peptide-based radiopharmaceutical asset for $50M upfront plus milestones, Sentynl Therapeutics and Fortress Biotech receive FDA approval for Zycubo targeting ATP7A protein for Menkes disease
Biotech & Pharma Updates | January 11 - 12, 2026
🧬 Eli Lilly + NVIDIA jointly invest $1B in AI co-innovation lab for drug discovery acceleration, Eli Lilly reportedly ready with €15B bid to acquire Abivax for ulcerative colitis drug obefazimod, Novartis + SciNeuro Pharmaceuticals partner on Alzheimer's anti-amyloid antibody program for $165M upfront + $1.5B milestones, Cellares expands cell therapy factory-in-a-box operations to Europe with new Netherlands manufacturing facility lease, Oricell Therapeutics raises $70M Series C to accelerate solid tumor CAR-T therapies development, Moderna hits $1.9B 2025 revenue goal while cutting operating expenses faster than expected amid cost reduction drive, Lynk Pharmaceuticals' zemprocitinib (LNK01001) hits Ph3 primary endpoint for JAK1 inhibition in rheumatoid arthritis, Sanofi's Teizeild (teplizumab) wins EU approval to delay onset of type 1 diabetes following Ph2 success
Biotech & Pharma Updates | January 8 - 11, 2026
🧬 Merck & Co. reportedly in talks to acquire Revolution Medicines for $28-32B amid competing buyout rumors, Roche + MediLink partner on B7H3-targeted ADC YL201 - $570M upfront and near-term milestones, Orca Bio raises $250M Series F for cell therapy commercialization and pipeline advancement, Novartis to build fourth US radioligand therapy manufacturing facility in Florida as part of $23B investment, AirNexis Therapeutics debuts with $200M series A funding to develop China-sourced COPD therapy AN01, Eikon Therapeutics files IPO for their immuno-responsive cancer treatments including TLR7/8 dual-agonist, Eli Lilly + Chai Discovery partner on AI drug design using Chai 1 and Chai 2 platforms